> Certain concomitant or recently administered medicinal products  including chemotherapy (systemic or intrathecal), anti -T-cell antibody- based therapies, extracorporeal photoph eresis or BRENTUXIMAB VEDOTIN could potentially impact the efficacy of EBVALLO . EBVALLO  should only be administered  after an adequate washout period of such agents. 
